» Articles » PMID: 33023453

Peripheral Arterial Disease in Persons with Diabetic Foot Ulceration: a Current Comprehensive Overview

Overview
Specialty Endocrinology
Date 2020 Oct 7
PMID 33023453
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

In developed countries, the prevalence of persons with diabetes and peripheral arterial disease (PAD) is approximately 50%. The presence of PAD is associated with non-healing ulcers, major amputation, cardiovascular morbidity, and mortality. It is estimated that persons with diabetes, foot ulceration and PAD have 50% of 5-years mortality rate. Therefore, subjects with ischemic diabetic foot ulcers (DFUs) should be considered a special group of patients with specific clinical characteristics, general health status and prognosis. In persons with ischemic DFUs, an early diagnosis and treatment are mandatory to reduce the risk of worse outcomes such as major amputation. Revascularization of occluded lower extremity arteries is the main treatment to restore blood flow in the foot and promote wound healing. Nonetheless, there are several unmet needs in the management of diabetic subjects with PAD and foot ulceration as medical therapy, diagnostic criteria and indications for revascularization, revascularization strategy and technical approach as well as the management of no-option critical limb ischemia patients. It is a common opinion that there is an evolution of PAD features in diabetic persons, which seems to present a more aggressive pattern. This may be related to the frequent presence of concomitant comorbidities such as renal failure which could influence the characteristics of atherosclerotic plaques and their distribution. The aim of this review is to commence a complete overview and state of the art in the treatment of patients with diabetes, PAD, and foot ulceration and to describe the current challenges and future perspectives.

Citing Articles

Retrospective cohort study on the safety and efficacy of paclitaxel-coated balloon in the treatment of diabetic subpatellar artery disease.

Lin F, Chen L, Liu Y, Yang R, Zhang X, Lin T Medicine (Baltimore). 2024; 103(50):e40759.

PMID: 39686438 PMC: 11651502. DOI: 10.1097/MD.0000000000040759.


The Immune-Centric Revolution Translated into Clinical Application: Peripheral Blood Mononuclear Cell (PBMNC) Therapy in Diabetic Patients with No-Option Critical Limb-Threatening Ischemia (NO-CLTI)-Rationale and Meta-Analysis of Observational....

Rehak L, Giurato L, Monami M, Meloni M, Scatena A, Panunzi A J Clin Med. 2024; 13(23).

PMID: 39685690 PMC: 11642624. DOI: 10.3390/jcm13237230.


Autologous cell therapy for ischemic diabetic foot: a meta-analysis of randomized controlled trials for the development of the Italian guidelines for the treatment of diabetic foot syndrome.

Scatena A, Apicella M, Mantuano M, Ragghianti B, Silverii A, Miranda C Acta Diabetol. 2024; .

PMID: 39545964 DOI: 10.1007/s00592-024-02393-z.


Vascular Impairment, Muscle Atrophy, and Cognitive Decline: Critical Age-Related Conditions.

de Lima E, Tanaka M, Lamas C, Quesada K, Detregiachi C, Cressoni Araujo A Biomedicines. 2024; 12(9).

PMID: 39335609 PMC: 11428869. DOI: 10.3390/biomedicines12092096.


Racial/ethnic disparities in chronic wounds: Perspectives on linking upstream factors to health outcomes.

Cavalcante-Silva J, Fantuzzi G, Minshall R, Wu S, Oddo V, Koh T Wound Repair Regen. 2024; 32(5):770-779.

PMID: 38943351 PMC: 11578790. DOI: 10.1111/wrr.13200.